Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Open positions

Postdoctoral scientist, Oncolytic parvoviruses, German Cancer Research Center (DKFZ), Heidelberg, Germany

Marchini’ laboratory ( at the German Cancer Research Center in Heidelberg is seeking a highly motivated post-doc scientist to work in the development of second generation parvovirus based vectors with improved anticancer abilities.

The rat H-1 parvovirus (H-1PV) is not pathogenic for humans and possesses oncolytic and oncosuppressive properties demonstrated in a number of in vitro and in vivo models. H-1 PV has recently been tested in a monocentric phase I/IIa trial in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain tumour in humans. Results show that virus treatment is well tolerated and is associated with first evidence of efficacy. However, further development is necessary to improve clinical outcome.
The successful candidate will be involved in a project aiming to reinforce the oncolytic activity of H-1PV by arming the virus with RNAi triggering molecules (e.g. a shRNA expression cassette, antisense oligonucleotides, or miRNAs) targeting oncogenes, anti-apoptotic genes or other cellular factors which impair viral replication/cytotoxicity in cancer cells.

The ideal candidate will have:
(i) A solid background in virology and cell biology with a great interest in oncolytic virus therapy
(ii) Previous experience in working with animal models of human cancers
(ii) Good publication record in well recognized international journals with at least two papers in journals with an impact factor higher than five
(iii) Strong organizational skills, problem solving, autonomy and ability to prioritize and meet deadlines.
(iv) Excellent verbal and written English

Previous experience in one of the following areas is desired: gene silencing, vecterology, immune checkpoint blockade and oncolytic virus-therapy.
The candidate will join a team of very motivated scientists in a stimulating environment participating in a very promising established project. The position is available immediately with an initial appointment of one year (renewable). The salary is based on the standard German scale.

Applications including cover letter, CV, list of publications and name of two referees should be sent by e-mail to:
Dr. Antonio Marchini

Deadline for job-applications: 31.1.2017

We are always looking for highly motivated and talented people to join our Team.
Please send your application together with a motivation letter to:

to top
powered by webEdition CMS